Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Drug-Eluting Material Aims to Curb SSIs

April 26, 2016 By Sam Brusco

Bacteria associated with mesh surgical site infections, like MRSA and E. coli, are both a threat to patient health and patient wallets. Among one of the riskier surgeries that use a mesh is ventral hernia repair, which can often result in high rates of infection.

The proliferation of these surgical site infections presented a need to develop a strategy for a new type of antimicrobial mesh. One such company developed a drug-eluting mesh that aims to prevent implantable surgical devices’ contamination by hitting a targeted area with bacteria-killing agents. In order to gain more insight on the mesh’s development, MDT spoke with Dr. Lisa Jennings, co-founder and chief scientific officer of Ariste Medical, the company that developed the mesh.

Dr. Jennings presenting the technology at the AHS in April 2016 in Washington, D.C.

What problem is the new antimicrobial graft addressing?

Dr. Jennings: Ariste’s technology is poised to drastically reduce bacterial colonization of surgical implants that are so often devastating to patients and care providers. In addition to infection, restenosis and thrombosis are common complications that lead to device failure. 

Why ventral hernia repair as the first application?

Dr. Jennings: With more than 350,000 ventral hernia procedures performed annually, open ventral hernia repair is among the most common surgeries in the United States, but often results in high rates of infection, excess morbidity and healthcare expenses. As our technology can greatly reduce these unfortunate outcomes, we felt we could have the greatest impact by first aiming to improve the hernia repair procedure.

Additionally, there is an obvious clinical need with the reported rates of infection particularly in patients that are obese, chronic smokers, or that suffer from uncontrolled diabetes or repeat hernia repair procedures. In addition, with the increased scrutiny of the biologic meshes in terms of infection rates, a new alternative is necessary.

How do antimicrobial “synthetics” succeed where biologics fail? (Why polypropylene?)

Dr. Jennings: Most of the earlier products were either soaked or dip-coated with anti-microbial agents. Ariste’s technology, the first polypropylene coated antimicrobial graft for open ventral hernia repair, provides a programmed drug-elution profile that may include a burst release, a near-linear release of drug, and a gradual elution over the course of at least 14 days. While infection may be evident within days of a surgical procedure, other signs of infection may be much longer, even weeks after open ventral hernia repair. Our timeframe may have added benefit in preserving the implant and inhibiting bacterial colonization of the mesh. Our initial mesh will be polypropylene since it is the most common mesh material used by physicians for ventral hernia repair.

Beyond hernia repair, what other potential applications might the mesh have?

Dr. Jennings: We are not limited to a certain implantable material or drug combination. We anticipate making a significant impact in alleviating complications due to device implantation such as infection, scar tissue formation or clotting.

Related Articles Read More >

This is a Zimmer Biomet marketing image of its Rosa robotic surgery system.
Zimmer Biomet seeks a ZBEdge for its Rosa robotic surgery
A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe